Rheumatology Advance Access published online on August 15, 2003
Rheumatology, doi:10.1093/rheumatology/keh003
Rheumatology © British Society for Rheumatology 2003; all rights reserved
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Original Papers
1 Department of Public Health and Epidemiology, University of Birmingham, Edgbaston, Birmingham, UK; Department of Rheumatology, Selly Oak Hospital, University Hospital Birmingham NHS Trust, Raddlebarn Road, Birmingham B29 6JD, UK
Received 14 May 2003
; accepted 7 July 2003
Objective. To determine the current disease-modifying anti-rheumatic drug (DMARD) preferences of UK consultant rheumatologists. Methods. A questionnaire was sent in May 2002. We asked which DMARD(s) was most frequently preferred first and sought the most typical sequence of DMARDs, including DMARD combinations. Also we determined the extent to which prognostic and other factors influenced treatment choices. Comments were invited, written responses abstracted and key themes identified. Results. After two mailings, 331 (of 460; 72%) suitable questionnaires were returned. Ninety-five per cent (315/331) preferred methotrexate (154, 46.5%) or sulphasalazine (144, 43.5%) or either of these two (17, 5%) as first-choice agent. Of those who chose methotrexate first, 80% (123/154) ranked sulphasalazine second, 45% (55/123) combined sulphasalazine and methotrexate and 49% (27/55) then added hydroxychloroquine to this combination, in active disease. Of those who chose sulphasalazine first, 95% (137/144) ranked methotrexate second, 75% (113/150) preferring methotrexate monotherapy and 12% (18/150) the combination with sulphasalazine. Rheumatologists who preferred sulphasalazine first more commonly used subsequent DMARDs singly than those who started with methotrexate (P < 0.0001). Leflunomide was more commonly preferred than intramuscular gold as third choice (52/145 vs 29/145; P < 0.003). The most popular sequence of DMARDs was methotrexate or sulphasalazine, singly or in combination, leflunomide, intramuscular gold and anti-tumour necrosis factor therapy. Poor prognostic factors influenced DMARD choice, but patient occupation and drug costs did not. Conclusion. Methotrexate has displaced other DMARDs, especially sulphasalazine, as agent of first choice and newer agents have displaced older DMARDs. Whether the expressed preference for particular DMARDs accurately reflects actual use, and is optimal in rheumatoid arthritis, remains to be determined.
Key words: Survey, DMARD, Prescribing preference, Rheumatologists, Rheumatoid arthritis.
A survey of British rheumatologists' DMARD preferences for rheumatoid arthritis
2 Department of Public Health and Epidemiology, University of Birmingham, Edgbaston, Birmingham, UK
3 Department of Rheumatology, Selly Oak Hospital, University Hospital Birmingham NHS Trust, Raddlebarn Road, Birmingham B29 6JD, UK
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A. McLean-Tooke, C. Aldridge, S. Waugh, G. P. Spickett, and L. Kay Methotrexate, rheumatoid arthritis and infection risk--what is the evidence? Rheumatology, August 1, 2009; 48(8): 867 - 871. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S L Hider, A Silman, D Bunn, S Manning, D Symmons, and M Lunt Comparing the long-term clinical outcome of treatment with methotrexate or sulfasalazine prescribed as the first disease-modifying antirheumatic drug in patients with inflammatory polyarthritis Ann Rheum Dis, November 1, 2006; 65(11): 1449 - 1455. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K M J Douglas, E Ladoyanni, G J Treharne, E D Hale, N Erb, and G D Kitas Cutaneous abnormalities in rheumatoid arthritis compared with non-inflammatory rheumatic conditions Ann Rheum Dis, October 1, 2006; 65(10): 1341 - 1345. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Rajakulendran and C. Deighton Do guidelines for the prescribing and monitoring of leflunomide need to be modified? Rheumatology, November 1, 2004; 43(11): 1447 - 1448. [Full Text] [PDF]
|
|